Arecor Therapeutics PLC (GB:AREC) has released an update.
Arecor Therapeutics PLC announced positive results from a Phase I clinical trial of its novel insulin formulation, AT278, which showed superior efficacy in Type 2 diabetics with high BMI compared to current treatments. AT278 is an ultra-concentrated and ultra-rapid acting insulin, potentially the first of its kind, targeting a significant unmet need for patients with high daily insulin requirements. The company is hosting a webinar with CEO Sarah Howell and Principal Investigator Professor Thomas Pieber to discuss these developments.
For further insights into GB:AREC stock, check out TipRanks’ Stock Analysis page.
